Abstract
Novelty: Novel amino acid prodrugs, said to have renin inhibitory activity and good aqueous solubility, are disclosed. The compounds are said to undergo selective, enzyme catalysed cleavage at the gut wall, resulting in increased local concentration and absorption. It is proposed that such compounds have greater bioavailability than presently known renin inhibitors and are said to have potential utility for the treatment of conditions such as hypertension, hyperaldosteronism, congestive heart failure and glaucoma.Biology: In vitro studies evaluating stability of novel compounds in rat intestinal perfusate (IP) and suspensions of rat brush border membranes (BBM), respectively, are described. An exemplified compound was found to have respective tlI2 values of 508.5 and 514.0 minutes, in IP and BBM (analysed by HPLC). This is said to demonstrate that compounds of the invention are prodrugs, activated by gut wall enzymes.Chemistry: The compound below is exemplified in the biological study. Preparative details using standard techniques, are presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
